论文部分内容阅读
目的:检测维甲酸受体β(RARβ)基因在宫颈癌组织中的表达及其意义。方法:收集该院68例宫颈癌和28例宫颈炎患者的临床资料和组织标本,RT-PCR法检测宫颈癌和宫颈炎组织中RARβmRNA的表达水平。采用免疫组织化学法和酶联免疫吸附试验检测宫颈癌和宫颈炎组织中RARβ蛋白的表达情况。统计两组临床资料并对随访的患者资料进行对比。结果:宫颈癌组中的RARβmRNA相对表达量低于宫颈炎组,宫颈癌组中的RARβ蛋白表达阳性比例低于宫颈炎组,宫颈癌组中的RARβ蛋白含量平均值低于宫颈炎组平均值,差异均具有统计学意义(P<0.05)。RARβ蛋白在宫颈癌Ⅲ/Ⅳ期阳性表达比例低于Ⅰ/Ⅱ期,差异具有统计学意义(P<0.05)。有淋巴结转移患者中RARβ表达阳性比例低于无淋巴结转移,差异具有统计学意义(P<0.05)。RARβ表达阴性的宫颈癌患者中死亡率和复发率高于阳性表达患者,差异均具有统计学意义(P<0.05)。结论:RARβ在宫颈癌的发生过程中发挥重要作用,故其可作为宫颈癌患者发生、发展和预后判断的重要参考指标。
Objective: To detect the expression of RARβ gene in cervical cancer and its significance. Methods: The clinical data and tissue samples of 68 cases of cervical cancer and 28 cases of cervicitis were collected. The expression of RARβ mRNA in cervical cancer and cervicitis was detected by RT-PCR. Immunohistochemistry and enzyme-linked immunosorbent assay were used to detect the expression of RARβ protein in cervical cancer and cervicitis. Statistics of two groups of clinical data and follow-up comparison of patient data. Results: The relative expression of RARβ mRNA in cervical cancer group was lower than that in cervicitis group. The positive rate of RARβ protein expression in cervical cancer group was lower than that in cervicitis group. The average content of RARβ protein in cervical cancer group was lower than that in cervicitis group , The differences were statistically significant (P <0.05). The positive rate of RARβ protein in stage Ⅲ / Ⅳ cervical cancer was lower than that in stage Ⅰ / Ⅱ, the difference was statistically significant (P <0.05). The positive rate of RARβ expression in patients with lymph node metastasis was lower than that without lymph node metastasis, the difference was statistically significant (P <0.05). The mortality and recurrence rate of patients with RARβ-negative cervical cancer were significantly higher than those with positive expression (P <0.05). Conclusion: RARβ plays an important role in the development of cervical cancer, so it can be used as an important reference for the occurrence, development and prognosis of cervical cancer.